MedTrace Logo

A Study of SARS-CoV-2 mRNA Vaccine (SYS6006) in Chinese Healthy Participants Aged 18 Years or More

NCT05439824 · Status: UNKNOWN · Phase: PHASE2 · Type: INTERVENTIONAL · Enrollment: 450

Last updated 2023-05-24

No results posted yet for this study

Summary

This is a phase 2, randomized, observer-blinded, placebo-controlled clinical study to evaluate the immunogenicity and safety of SARS-CoV-2 mRNA Vaccine (SYS6006）in healthy participants aged 18 or more.

Conditions

Interventions

BIOLOGICAL

SYS6006 20 μg

SARS-CoV-2 mRNA Vaccine

BIOLOGICAL

SYS6006 30 μg

SARS-CoV-2 mRNA Vaccine

BIOLOGICAL

Placebo

Placebo

Sponsors & Collaborators

  • CSPC ZhongQi Pharmaceutical Technology Co., Ltd.

    lead INDUSTRY

Principal Investigators

  • Yuliang Zhao · Center For Disease Control and Prevention, Hebei Province

  • Jingxin Li · Jiangsu Provincial Center for Disease Control and Prevention

  • Xiang Lu · Nanjing Medical University

Study Design

Allocation
RANDOMIZED
Purpose
PREVENTION
Masking
TRIPLE
Model
PARALLEL

Eligibility

Min Age
18 Years
Sex
ALL
Healthy Volunteers
Yes

Timeline & Regulatory

Start
2022-06-28
Primary Completion
2023-01-12
Completion
2023-06-28

Countries

  • China

Study Locations

More Related Trials

Entities

Drugs
Diseases

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT05439824 on ClinicalTrials.gov